-
admin
Posts
AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech
MACAO, May 31, 2026 /PRNewswire/ — The BEYOND Expo 2026 has shown what the future looks like as it delivers on its mission of ‘Empowering Asia,...
Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders
SHANGHAI, May 31, 2026 /PRNewswire/ — The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards....
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI...
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
CHENGDU, China, May 31, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that the results of the Phase III clinical study...
Global Times: Chinese artisan weaves Zhuang brocade into World Cup
Global Times: Guangxi’s Zhuang brocade becomes official FIFA World Cup merchandise, showcasing China’s cultural heritage. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — Incorporating elements...
Global Times: At 80, award winning illustrator Cai Gao still draws inspiration from childhood
Global Times: Cai Gao, China’s first Hans Christian Andersen Award winner, blends tradition and childhood wonder across 50 years of art. Beijing, CHINA, May 30,...
Global Times: China demonstrates remarkable ability to set a long-term vision and actually execute it
Global Times: Expert Chandran Nair sees China’s 15th Five-Year Plan as a global stability anchor, prioritising rural growth and sustainability. Beijing, CHINA, May 30, 2026...
Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours
ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients...
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated...
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard...
